Chinese quality control indices for standardized diagnosis and treatment of renal cancer (2022 edition)

Lin Yao¹, Yicong Du¹, Wen Dong², Xianshu Gao³, Jun Guo⁴, Jianxing Qiu⁵, Qiang Wei⁶, Shikai Wu⁷, Dingwei Ye⁸, Wei Yu¹, Hao Zeng⁶, Qian Zhang¹, Yong Zhang⁹, Zhiling Zhang¹⁰, Fangjian Zhou¹⁰, Wenjing Yang¹¹, Hui Wang¹¹, Xu Zhang¹², Zhisong He¹; for Renal Cancer Quality Control Experts Committee of National Cancer Quality Control Center, National Cancer Center of the People's Republic of China

Affiliations

¹ Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China.
² Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
³ Department of Radiation Oncology, Peking University First Hospital, Beijing, China.
⁴ Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.
⁵ Department of Radiology, Peking University First Hospital, Beijing, China.
⁶ Department of Urology, West China Hospital, Sichuan University, Chengdu, China.
⁷ Department of Oncology, Peking University First Hospital, Beijing, China.
⁸ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
⁹ Department of Urology Surgery, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
¹⁰ Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
¹¹ Office for Cancer Diagnosis and Treatment Quality Control, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
¹² Department of Urology, The Third Medical Center, Chinese People Liberation Army (PLA) General Hospital, Beijing, China.

PMID: 39036384
PMCID: PMC11256713
DOI: 10.1016/j.jncc.2023.11.004

Chinese quality control indices for standardized diagnosis and treatment of renal cancer (2022 edition)

Lin Yao et al. J Natl Cancer Cent. 2023.

. 2023 Dec 7;4(1):6-13.

doi: 10.1016/j.jncc.2023.11.004. eCollection 2024 Mar.

Authors

Affiliations

¹ Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China.
² Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
³ Department of Radiation Oncology, Peking University First Hospital, Beijing, China.
⁴ Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.
⁵ Department of Radiology, Peking University First Hospital, Beijing, China.
⁶ Department of Urology, West China Hospital, Sichuan University, Chengdu, China.
⁷ Department of Oncology, Peking University First Hospital, Beijing, China.
⁸ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
⁹ Department of Urology Surgery, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
¹⁰ Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
¹¹ Office for Cancer Diagnosis and Treatment Quality Control, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
¹² Department of Urology, The Third Medical Center, Chinese People Liberation Army (PLA) General Hospital, Beijing, China.

PMID: 39036384
PMCID: PMC11256713
DOI: 10.1016/j.jncc.2023.11.004

Abstract

Renal cancer is one of the most common malignancies of the urinary system, and the number of deaths continues to increase. The standardized management of the diagnosis and treatment of renal cancer is challenging due to the great differences in the diagnosis and treatment of renal cancer in different regions. The Renal Cancer Expert Committee of the National Cancer Quality Control Center (NCQCC) identified a lack of authoritative quality control standards as an opportunity to utilize its multidisciplinary membership to improve the standardized diagnosis and treatment of renal cancer. The Renal Cancer Expert Committee of the NCQCC aims to promote quality control and national standardization, uniformity, and normalization of renal cancer diagnosis and treatment, which ultimately improved the survival rate and quality of life of renal cancer patients. A panel of experts with renal cancer surgery, renal cancer medicine, medical imaging, pathology and radiotherapy were drawn together and determined the quality control standards for the standardized diagnosis and treatment of renal cancer. The Indices includes 20 items that cover all key areas in the diagnosis and treatment of renal cancer, such as standard diagnosis, surgery treatment, systemic treatment, and prognostic evaluation.

Keywords: Quality control index; Renal cancer; Standardized diagnosis and treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Cited by

Multiomics Analysis of Exportin Family Reveals XPO1 as a Novel Target for Clear Cell Renal Cell Carcinoma.
Hao Y, Lv H, Yan X, Liang Y, Jiang A, Zhao Y. Hao Y, et al. Int J Genomics. 2025 Jan 21;2025:3645641. doi: 10.1155/ijog/3645641. eCollection 2025. Int J Genomics. 2025. PMID: 39882192 Free PMC article.

References

1. Zheng RS, Zhang SW, Zeng HM, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2(1):1–9. doi: 10.1016/j.jncc.2022.02.002. - DOI
1. Bureau of Medical Administration National health commission of the People's Republic of China. Quality Control Index for Standardized Diagnosis and Treatment of Renal Cancer in China (2022 Edition) 2022;44(12):1256–1261. doi: 10.3760/cma.j.cn112152-20220803-00533. - DOI
1. Huang J, Wang JY, Kong CZ, et al. In: Chinese Guidelines for the Diagnosis and Treatment of Urological and Andrological Diseases. 2019 ed. Huang J, Wang JY, Kong CZ, et al., editors. Science Press; 2019. Guidelines for diagnosis and treatment of renal cell cancer; pp. 1–26. Book in Chinese.
1. Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol. 2018;73(4):560–569. doi: 10.1016/j.eururo.2017.12.018. - DOI - PubMed
1. Performance Appraisal Leadership Group . Chinese Operation Manual of Performance Appraisal of National Tertiary Public Hospitals (2022 Edition) March 2022. National health commission tertiary public hospital.
2. Accessed November 17, 2023. http://www.nhc.gov.cn/cms-search/downFiles/d5b01488579745f79295852f8368f127.pdf?eqid=819bc422000900e100000003642e3495&eqid=9bf1def500751e7600000002643f2f7a.

LinkOut - more resources

Full Text Sources
- Elsevier Science
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Chinese quality control indices for standardized diagnosis and treatment of renal cancer (2022 edition)

Affiliations

Chinese quality control indices for standardized diagnosis and treatment of renal cancer (2022 edition)

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Related information

LinkOut - more resources

Full Text Sources